Brought to you by 
Agendia BV raises $23mm through Series E round
02 Oct 2009
Executive Summary
Agendia BV (gene expression profiling for personalized cancer diagnostics) raised $23mm through its Series E round. An unidentified family investment firm provided half of the funds, two individual investors contributed $1mm each, and the company's existing backers invested the rest.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com